Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Long-Term Investments (2016 - 2021)

Karyopharm Therapeutics' Long-Term Investments history spans 8 years, with the latest figure at $2.0 million for Q3 2021.

  • For Q3 2021, Long-Term Investments fell 94.91% year-over-year to $2.0 million; the TTM value through Sep 2021 reached $2.0 million, down 94.91%, while the annual FY2020 figure was $24.2 million, 1101.14% up from the prior year.
  • Long-Term Investments reached $2.0 million in Q3 2021 per KPTI's latest filing, roughly flat from $2.0 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $48.9 million in Q2 2020 to a low of $2.0 million in Q4 2018.
  • Average Long-Term Investments over 5 years is $19.5 million, with a median of $10.3 million recorded in 2018.
  • Peak YoY movement for Long-Term Investments: skyrocketed 1847.13% in 2020, then tumbled 95.89% in 2021.
  • A 5-year view of Long-Term Investments shows it stood at $29.4 million in 2017, then tumbled by 93.19% to $2.0 million in 2018, then grew by 0.75% to $2.0 million in 2019, then surged by 1101.14% to $24.2 million in 2020, then tumbled by 91.72% to $2.0 million in 2021.
  • Per Business Quant, the three most recent readings for KPTI's Long-Term Investments are $2.0 million (Q3 2021), $2.0 million (Q2 2021), and $7.7 million (Q1 2021).